Support and Resistance Basics

What is MACD and how to read it?

How RSI can help?
RSI : 000

Stock Summary

Top Correlated Resources

CBLI


In the News

11:22 13 Aug 2022 CBLI

Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript

Cytocom, Inc. (CBLI) CEO Michael Handley on Q2 2021 Results - Earnings Call Transcript

07:30 13 Aug 2022 CBLI

Cytocom, Inc. Reports Second Quarter 2021 Financial Results

FORT COLLINS, Colo., Aug. 16, 2021 /PRNewswire/ -- Cytocom, Inc. (Nasdaq: CBLI), a leading biopharmaceutical company creating next-generation immune therapies for serious medical conditions that induce immune restoration and homeostasis, today reported recent corporate updates and financial results for the Company for the second quarter ended June 30, 2021, a period of time prior to the completion of the merger between legacy Cleveland BioLabs and the formerly private Cytocom Inc. Following the completion of the merger on July 27, 2021, Cytocom, Inc. emerged as a publicly traded entity.

07:30 13 Aug 2022 CBLI

Cytocom, Inc. Announces Participation at Liberty University's Empowering the Kingdom Through Business Conference

FORT COLLINS, Colo., Aug. 11, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the company will participate at the Empowering the Kingdom through Business Conference hosted by the Liberty University School of Business on August 10-12, 2021.

07:30 13 Aug 2022 CBLI

Cytocom, Inc. to Report Second Quarter 2021 Financial Results

FORT COLLINS, Colo., Aug. 10, 2021 /PRNewswire/ -- Cytocom, Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today announced that the Company will host a conference call and live audio webcast on Monday, August 16, 2021, at 8:30 a.m.

07:30 13 Aug 2022 CBLI

Cytocom Inc. Provides Updates on Key Clinical Programs for Crohn's Disease, Hematology, Pancreatic Cancer and COVID-19

FORT COLLINS, Colo., Aug. 9, 2021 /PRNewswire/ -- Cytocom Inc.  (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided an update regarding its portfolio of clinical programs.

07:33 13 Aug 2022 CBLI

Cytocom Inc. Provides Update on Completed Merger with Cleveland BioLabs

FORT COLLINS, Colo., Aug. 5, 2021 /PRNewswire/ -- Cytocom Inc. (NASDAQ: CBLI), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasis, today provided shareholders with an update regarding its recent merger with Cleveland BioLabs.

07:33 13 Aug 2022 CBLI

Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing

FORT COLLINS, Colo., July 29, 2021 /PRNewswire/ -- Cytocom, Inc., (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for $90 million in committed capital.

09:16 13 Aug 2022 CBLI

Cleveland BioLabs, Inc. and Cytocom Inc. Announce Call to Discuss Stockholder Meeting Vote Results and Proposed Merger

FORT COLLINS, Colo. and BUFFALO, N.Y.

05:58 13 Aug 2022 CBLI

CBLI Stock Price Increases Over 15% Pre-Market: Why It Happened

The stock price of Cleveland BioLabs, Inc. (Nasdaq: CBLI) increased by over 15% pre-market. This is why it happened.

06:37 13 Aug 2022 CBLI

Cleveland BioLabs, Inc. and Cytocom Announce Registration Statement and Proxy Statement for Previously Announced Merger Declared Effective by SEC

FORT COLLINS, Colo. and BUFFALO, N.Y.

Financial details

Company Rating
Buy
Market Cap
49.07M
Income
-2.64M
Revenue
43.65K
Book val./share
0.87
Cash/share
0.89
Dividend
-
Dividend %
-
Employees
18
Optionable
No
Shortable
Yes
Earnings
15 May 2020
P/E
-18.6
Forward P/E
-
PEG
12.6
P/S
1124.26
P/B
3.63
P/C
0.25
P/FCF
-18.21
Quick Ratio
45.83
Current Ratio
45.98
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.2
EPS next Y
-
EPS next Q
-
EPS this Y
-17.39%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-4.56%
Revenue last 5Y
-40.47%
Revenue Q/Q
-
EPS Q/Q
6.52%
-
-
-
-
SMA20
-19.23%
SMA50
-12.5%
SMA100
-69.57%
Inst Own
0%
Inst Trans
0%
ROA
-19%
ROE
-38%
ROC
-0.2%
Gross Margin
100%
Oper. Margin
-6348%
Profit Margin
-6044%
Payout
-
Shs Outstand
15.47M
Shs Float
7.69M
-
-
-
-
Target Price
-
52W Range
2.7-5.64
52W High
-95.6%
52W Low
-88.99%
RSI
43.88
Rel Volume
3.27
Avg Volume
156.95K
Volume
513.25K
Perf Week
2.42%
Perf Month
-7.71%
Perf Quarter
-
Perf Half Y
-77.06%
-
-
-
-
Beta
0.683695
-
-
Volatility
0%, 0.03%
Prev Close
2.51%
Price
0.2202
Change
3.14%

Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2020-12-31

Metric History 2016-12-312017-12-312018-12-312019-12-31 2020-12-31
Revenue per share
0.320.170.10.10.02
Net income per share
-0.24-0.87-0.32-0.23-0.19
Operating cash flow per share
-0.46-0.59-0.41-0.24-0.19
Free cash flow per share
-0.46-0.59-0.41-0.24-0.19
Cash per share
1.390.790.360.140.18
Book value per share
1.170.660.320.090.16
Tangible book value per share
1.170.660.320.090.16
Share holders equity per share
1.170.660.320.090.16
Interest debt per share
00000.21
Market cap
18.57M35.93M17.76M35.59M56.9M
Enterprise value
11.67M31.7M14.14M34.46M57.6M
P/E ratio
-6.98-3.7-4.92-13.45-23.72
Price to sales ratio
5.2818.4415.6131.96216.4
POCF ratio
-3.68-5.43-3.85-13.36-23.98
PFCF ratio
-3.68-5.43-3.83-13.35-23.98
P/B Ratio
1.454.854.9136.1628.26
PTB ratio
1.454.854.9136.1628.26
EV to sales
3.3216.2712.4330.95219.04
Enterprise value over EBITDA
-4.5-3.27-3.94-13.09-24.13
EV to operating cash flow
-2.31-4.79-3.07-12.94-24.27
EV to free cash flow
-2.31-4.79-3.05-12.93-24.27
Earnings yield
-0.14-0.27-0.2-0.07-0.04
Free cash flow yield
-0.27-0.18-0.26-0.07-0.04
Debt to equity
00000
Debt to assets
0.190.230.20.520.13
Net debt to EBITDA
2.660.441.010.43-0.29
Current ratio
5.114.334.911.97.6
Interest coverage
00000
Income quality
1.90.681.281.010.99
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
0.961.282.041.638.21
Research and developement to revenue
1.852.593.181.492.63
Intangibles to total assets
00000
Capex to operating cash flow
000.0100
Capex to revenue
00-0.0200
Capex to depreciation
-0.16-0.21-1.53-0.110
Stock based compensation to revenue
00000.05
Graham number
2.523.591.520.680.84
ROIC
-0.49-0.76-1.33-2.4-1.28
Return on tangible assets
-0.17-1.01-0.8-1.3-1.03
Graham Net
1.130.620.30.070.16
Working capital
12.78M7.37M3.56M950.11K2.01M
Tangible asset value
00000
Net current asset value
12.78M7.36M3.56M950.11K2.01M
Invested capital
00001.31
Average receivables
365.78K466.67K315.36K378.87K195.19K
Average payables
300K232.48K201.35K263.57K215.67K
Average inventory
00000
Days sales outstanding
36.59103.8780.76124.215.98
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
9.983.514.522.9422.84
Payables turnover
00000
Inventory turnover
00000
ROE
-0.21-1.31-1-2.69-1.19
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2021-06-30 for Q2

Metric History 2020-06-302020-09-302020-12-312021-03-31 2021-06-30
Revenue per share
0.010000
Net income per share
-0.03-0.06-0.05-0.04-0.04
Operating cash flow per share
-0.04-0.05-0.06-0.03-0.06
Free cash flow per share
-0.04-0.05-0.06-0.03-0.06
Cash per share
0.320.230.171.030.89
Book value per share
0.280.210.150.650.87
Tangible book value per share
0.280.210.1510.87
Share holders equity per share
0.280.210.150.650.87
Interest debt per share
000.1600
Market cap
30.7M25.61M44.86M74.69M84.67M
Enterprise value
27.3M22.89M45.04M60.33M70.89M
P/E ratio
-20.76-8.59-16.14-34.7-32.1
Price to sales ratio
485.41586.89170602.11B00
POCF ratio
-64.45-37.52-56.9-205.71-98.4
PFCF ratio
-64.45-37.52-56.9-205.71-98.4
P/B Ratio
9.339.3222.288.16.26
PTB ratio
9.339.3222.288.16.26
EV to sales
431.51524.54171282.86B00
Enterprise value over EBITDA
-74.38-30.95-65.08-109.79-105.95
EV to operating cash flow
-57.29-33.54-57.13-166.16-82.39
EV to free cash flow
-57.29-33.54-57.13-166.16-82.39
Earnings yield
-0.01-0.03-0.02-0.01-0.01
Free cash flow yield
-0.02-0.03-0.020-0.01
Debt to equity
00000
Debt to assets
0.190.150.130.040.02
Net debt to EBITDA
9.293.68-0.2626.1320.59
Current ratio
5.176.667.628.3645.98
Interest coverage
0-272.79000
Income quality
1.290.921.130.671.3
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
7.6716.012251.15B00
Research and developement to revenue
2.692.7703.62B00
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00.31000
Graham number
0.440.520.430.740.92
ROIC
-0.18-0.28-0.39-0.04-0.05
Return on tangible assets
-0.09-0.23-0.3-0.04-0.05
Graham Net
0.260.20.150.990.87
Working capital
3.28M2.74M2.01M14.18M13.52M
Tangible asset value
00000
Net current asset value
3.28M2.74M2.01M14.18M13.52M
Invested capital
001.0600
Average receivables
00000
Average payables
305.67K295.14K238.75K309.72K185.11K
Average inventory
00000
Days sales outstanding
350.8278.813940.34B00
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
0.260.32000
Payables turnover
00000
Inventory turnover
00000
ROE
-0.11-0.27-0.35-0.06-0.05
Capex per share
00000

Something similar

Same Sector
Same Price Range
Similar Market Cap